Tectonic Therapeutic Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
60
- Stock Symbol
-
TECX
- Investments
-
1
- Share Price
-
$20.73
- (As of Friday Closing)
Tectonic Therapeutic General Information
Description
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Contact Information
Website
www.tectonictx.comCorporate Office
- 490 Arsenal Way
- Suite 210
- Watertown, MA 02472
- United States
Corporate Office
- 490 Arsenal Way
- Suite 210
- Watertown, MA 02472
- United States
Tectonic Therapeutic Timeline
Tectonic Therapeutic Stock Performance
As of 20-Nov-2026, Tectonic Therapeutic’s stock price is $20.73. Its current market cap is $405M with 19.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $20.73 | $21.04 | $16.77 - $39.53 | $405M | 19.5M | 212K | -$4.63 |
Tectonic Therapeutic Financials Summary
As of 30-Sep-2026, Tectonic Therapeutic has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 232,636 | 123,225 | 525,021 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (95,448) | (82,780) | (60,491) | (41,774) |
| Net Income | (88,099) | (74,151) | (57,982) | (42,823) |
| Total Assets | 243,860 | 261,038 | 152,905 | 39,399 |
| Total Debt | 3,918 | 1,276 | 3,303 | 4,343 |
Tectonic Therapeutic Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tectonic Therapeutic Comparisons
Industry
Financing
Details
Tectonic Therapeutic Competitors (4)
One of Tectonic Therapeutic’s 4 competitors is Certa Therapeutics, a Venture Capital-Backed company based in Melbourne, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Certa Therapeutics | Venture Capital-Backed | Melbourne, Australia | ||||
| Confo Therapeutics | Venture Capital-Backed | Ghent, Belgium | ||||
| Longboard Pharmaceuticals | Formerly VC-backed | La Jolla, CA | ||||
| Escient Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Tectonic Therapeutic Patents
Tectonic Therapeutic Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240409601-A1 | Relaxin-2 fusion protein analogs and methods of using same | Active | 18-May-2023 | ||
| WO-2024238955-A2 | Relaxin-2 fusion protein analogs and methods of using same | Inactive | 18-May-2023 | ||
| WO-2024238955-A3 | Relaxin-2 fusion protein analogs and methods of using same | Inactive | 18-May-2023 | ||
| WO-2024044659-A1 | Constitutively active g protein-coupled receptor compositions and methods of use thereof | Inactive | 24-Aug-2022 | ||
| CA-3237801-A1 | Relaxin-2 fusion protein analogs and methods of using same | Pending | 11-Nov-2021 | C07K14/64 |
Tectonic Therapeutic Signals
Tectonic Therapeutic Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tectonic Therapeutic Acquisitions (1)
Tectonic Therapeutic’s most recent deal was a Merger/Acquisition with AVROBIO. The deal was made on 20-Jun-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AVROBIO | 20-Jun-2024 | Merger/Acquisition | Drug Discovery |
Tectonic Therapeutic ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.94 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Tectonic Therapeutic FAQs
-
When was Tectonic Therapeutic founded?
Tectonic Therapeutic was founded in 2019.
-
Where is Tectonic Therapeutic headquartered?
Tectonic Therapeutic is headquartered in Watertown, MA.
-
What is the size of Tectonic Therapeutic?
Tectonic Therapeutic has 60 total employees.
-
What industry is Tectonic Therapeutic in?
Tectonic Therapeutic’s primary industry is Drug Discovery.
-
Is Tectonic Therapeutic a private or public company?
Tectonic Therapeutic is a Public company.
-
What is Tectonic Therapeutic’s stock symbol?
The ticker symbol for Tectonic Therapeutic is TECX.
-
What is the current stock price of Tectonic Therapeutic?
As of 20-Nov-2026 the stock price of Tectonic Therapeutic is $20.73.
-
What is the current market cap of Tectonic Therapeutic?
The current market capitalization of Tectonic Therapeutic is $405M.
-
Who are Tectonic Therapeutic’s competitors?
Certa Therapeutics, Confo Therapeutics, Longboard Pharmaceuticals, and Escient Pharmaceuticals are competitors of Tectonic Therapeutic.
-
What is Tectonic Therapeutic’s annual earnings per share (EPS)?
Tectonic Therapeutic’s EPS for 12 months was -$4.63.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process